A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41416-023-02380-1
PubMed Identifier: 37537253
Publication URI: http://europepmc.org/abstract/MED/37537253
Type: Journal Article/Review
Volume: 129
Parent Publication: British journal of cancer
Issue: 6
ISSN: 0007-0920